MAPT and Alzheimer disease: For patients with prodromal AD vs controls, there were no significant differences in AUROCs between the tau biomarkers, but 18F-AV-1451 in tau stage I–IV, CSF t-tau, and CSF p-tau all had significantly higher AUROCs than hippocampal volume.